AS
Therapeutic Areas
Vyne Therapeutics Pipeline
| Drug | Indication | Phase |
|---|---|---|
| VYN201 | Non-segmental Vitiligo | Phase 1b |
| VYN202 | Undisclosed Systemic Inflammatory Diseases | Preclinical |
| YB-101 (GS-098) | Graves' Disease & Thyroid Eye Disease | Phase 1b/2b (Planned) |
Leadership Team at Vyne Therapeutics
DD
David Domzalski
President & Chief Executive Officer
TZ
Tyler Zeronda
Chief Financial Officer
IS
Iain Stuart
Chief Scientific Officer
RW
Roderick Wong, M.D.
Managing Partner, RTW Investments (Expected Exec. Chairman)
JH
Jason Hoitt
Expected CEO of Combined Company (CEO of Yarrow)